Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

BACKGROUND: LUX-Lung 3 showed afatinib improved progression-free survival (PFS) compared with cisplatin plus pemetrexed in patients with epidermal growth factor receptor (EGFR) mutations. In this study, chemotherapy efficacy tended to differ between patients with Leu858Arg (L858R) point mutation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneda, Toshihiko, Yoshioka, Hiroshige, Tamiya, Motohiro, Tamiya, Akihiro, Hata, Akito, Okada, Asukaka, Niwa, Takashi, Shiroyama, Takayuki, Kanazu, Masaki, Ishida, Tadashi, Katakami, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749021/
https://www.ncbi.nlm.nih.gov/pubmed/29291705
http://dx.doi.org/10.1186/s12885-017-3952-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749021/
https://www.ncbi.nlm.nih.gov/pubmed/29291705
http://dx.doi.org/10.1186/s12885-017-3952-7

Ejemplares similares